Protein kinase Cα as a heart failure therapeutic target

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 4, 2011, Pages 474-478

  Liu, Qinghang ^a   Molkentin, Jeffery D ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Cardiovascular; Heart failure; Hypertrophy; Protein kinase C; Ruboxistaruin; Signaling

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 3 [8 [(DIMETHYLAMINO)METHYL] 6,7,8,9 TETRAHYDROPYRIDO[1,2 A]INDOL 10 YL] 4 (1 METHYL 1H INDOL 3 YL) 1H PYRROLE 2,5 DIONE; BETA ADRENERGIC RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 2; PHOSPHOLAMBAN; PROTEIN INTERACTING WITH PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C ALPHA INHIBITOR; PROTEIN KINASE C BETA; PROTEIN KINASE C GAMMA; PROTEIN KINASE C INTERACTING COUSIN OF THIOREDOXIN; RUBOXISTAURIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SOTRASTAURIN; UNCLASSIFIED DRUG;

DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE DELETION; GENETIC ANALYSIS; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION; HEART FAILURE; HUMANS; MICE; MICE, KNOCKOUT; MOLECULAR TARGETED THERAPY; MYOCARDIAL CONTRACTION; MYOCARDIUM; PROTEIN KINASE C-ALPHA; PROTEIN KINASE INHIBITORS;

MUS; RODENTIA;

EID: 80052801123     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.10.004     Document Type: Review

References (43)

1. Dorn G.W., Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005, 115:527-537.
2. House C., Kemp B.E. Protein kinase C contains a pseudosubstrate prototope in its regulatory domain. Science 1987, 238:1726-1728.
3. Churchill E., Budas G., Vallentin A., Koyanagi T., Mochly-Rosen D. PKC isozymes in chronic cardiac disease: possible therapeutic targets?. Annu Rev Pharmacol Toxicol 2008, 48:569-599.
4. Sabri A., Steinberg S.F. Protein kinase C isoform-selective signals that lead to cardiac hypertrophy and the progression of heart failure. Mol Cell Biochem 2003, 251:97-101.
5. Goldberg M., Steinberg S.F. Tissue-specific developmental regulation of protein kinase C isoforms. Biochem Pharmacol 1996, 51:1089-1093.
6. Hambleton M., Hahn H., Pleger S.T., Kuhn M.C., Klevitsky R., Carr A.N., et al. Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation 2006, 114:574-582.
7. Pass J.M., Gao J., Jones W.K., Wead W.B., Wu X., Zhang J., et al. Enhanced PKC beta II translocation and PKC beta II-RACK1 interactions in PKC epsilon-induced heart failure: a role for RACK1. Am J Physiol Heart Circ Physiol 2001, 281:H2500-H2510.
8. Ping P., Zhang J., Qiu Y., Tang X.L., Manchikalapudi S., Cao X., et al. Ischemic preconditioning induces selective translocation of protein kinase C isoforms epsilon and eta in the heart of conscious rabbits without subcellular redistribution of total protein kinase C activity. Circ Res 1997, 81:404-414.
9. Gu X., Bishop S.P. Increased protein kinase C and isozyme redistribution in pressure-overload cardiac hypertrophy in the rat. Circ Res 1994, 75:926-931.
10. Jalili T., Takeishi Y., Song G., Ball N.A., Howles G., Walsh R.A. PKC translocation without changes in Galphaq and PLC-beta protein abundance in cardiac hypertrophy and failure. Am J Physiol Heart Circ Physiol 1999, 277:H2298-H2304.
11. De Windt L.J., Lim H.W., Haq S., Force T., Molkentin J.D. Calcineurin promotes protein kinase C and c-Jun NH2-terminal kinase activation in the heart. Cross-talk between cardiac hypertrophic signaling pathways. J Biol Chem 2000, 275:13571-13579.
12. Bayer A.L., Heidkamp M.C., Patel N., Porter M., Engman S., Samarel A.M. Alterations in protein kinase C isoenzyme expression and autophosphorylation during progression of pressure overload-induced left ventricular hypertrophy. Mol Cell Biochem 2003, 242:145-152.
13. Braun M.U., LaRosee P., Schon S., Borst M.M., Strasser R.H. Differential regulation of cardiac protein kinase C isozyme expression after aortic banding in rat. Cardiovasc Res 2002, 56:52-63.
14. Wang J., Paradis P., Aries A., Komati H., Lefebvre C., Wang H., et al. Convergence of protein kinase C and JAK-STAT signaling on transcription factor GATA-4. Mol Cell Biol 2005, 25:9829-9844.
15. Simonis G., Briem S.K., Schoen S.P., Bock M., Marquetant R., Strasser R.H. Protein kinase C in the human heart: differential regulation of the isoforms in aortic stenosis or dilated cardiomyopathy. Mol Cell Biochem 2007, 305:103-111.
16. Bowling N., Walsh R.A., Song G., Estridge T., Sandusky G.E., Fouts R.L., et al. Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation 1999, 99:384-391.
17. Braz J.C., Gregory K., Pathak A., Zhao W., Sahin B., Klevitsky R., et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 2004, 10:248-254.
18. Hahn H.S., Marreez Y., Odley A., Sterbling A., Yussman M.G., Hilty K.C., et al. Protein kinase Calpha negatively regulates systolic and diastolic function in pathological hypertrophy. Circ Res 2003, 93:1111-1119.
19. Liu Q., Chen X., Macdonnell S.M., Kranias E.G., Lorenz J.N., Leitges M., et al. Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach. Circ Res 2009, 105:194-200.
20. Hambleton M., York A., Sargent M.A., Kaiser R.A., Lorenz J.N., Robbins J., et al. Inducible and myocyte-specific inhibition of PKCalpha enhances cardiac contractility and protects against infarction-induced heart failure. Am J Physiol Heart Circ Physiol 2007, 293:H3768-H3771.
21. Tian R., Miao W., Spindler M., Javadpour M.M., McKinney R., Bowman J.C., et al. Long-term expression of protein kinase C in adult mouse hearts improves postischemic recovery. Proc Natl Acad Sci USA 1999, 96:13536-13541.
22. Jeong D., Cha H., Kim E., Kang M., Yang D.K., Kim J.M., et al. PICOT inhibits cardiac hypertrophy and enhances ventricular function and cardiomyocyte contractility. Circ Res 2006, 99:307-314.
23. Dorn G.W.,.2nd, Molkentin J.D. Manipulating cardiac contractility in heart failure: data from mice and men. Circulation 2004, 109:150-158.
24. Malhotra R., D'Souza K.M., Staron M.L., Birukov K.G., Bodi I., Akhter S.A. G alpha(q)-mediated activation of GRK2 by mechanical stretch in cardiac myocytes: the role of protein kinase C. J Biol Chem 2010, 285:13748-13760.
25. Koch W.J. Genetic and phenotypic targeting of beta-adrenergic signaling in heart failure. Mol Cell Biochem 2004, 263:5-9.
26. Belin R.J., Sumandea M.P., Allen E.J., Schoenfelt K., Wang H., Solaro R.J., et al. Augmented protein kinase C-alpha-induced myofilament protein phosphorylation contributes to myofilament dysfunction in experimental congestive heart failure. Circ Res 2007, 101:195-204.
27. Sumandea M.P., Pyle W.G., Kobayashi T., de Tombe P.P., Solaro R.J. Identification of a functionally critical protein kinase C phosphorylation residue of cardiac troponin T. J Biol Chem 2003, 278:35135-35144.
28. Kooij V., Boontje N., Zaremba R., Jaquet K., dos Remedios C., Stienen G.J., et al. Protein kinase C alpha and epsilon phosphorylation of troponin and myosin binding protein C reduce Ca2+ sensitivity in human myocardium. Basic Res Cardiol 2010, 105:289-300.
29. Hidalgo C., Hudson B., Bogomolovas J., Zhu Y., Anderson B., Greaser M., et al. PKC phosphorylation of titin's PEVK element: a novel and conserved pathway for modulating myocardial stiffness. Circ Res 2009, 105:631-638.
30. Huang L., Wolska B.M., Montgomery D.E., Burkart E.M., Buttrick P.M., Solaro R.J. Increased contractility and altered Ca(2+) transients of mouse heart myocytes conditionally expressing PKCbeta. Am J Physiol Cell Physiol 2001, 280:C1114-C1120.
31. Wang H., Grant J.E., Doede C.M., Sadayappan S., Robbins J., Walker J.W. PKC-betaII sensitizes cardiac myofilaments to Ca2+ by phosphorylating troponin I on threonine-144. J Mol Cell Cardiol 2006, 41:823-833.
32. Yang L., Doshi D., Morrow J., Katchman A., Chen X., Marx S.O. Protein kinase C isoforms differentially phosphorylate Ca(v)1.2 alpha(1c). Biochemistry 2009, 48:6674-6683.
33. Sussman M.A., Hamm-Alvarez S.F., Vilalta P.M., Welch S., Kedes L. Involvement of phosphorylation in doxorubicin-mediated myofibril degeneration. An immunofluorescence microscopy analysis. Circ Res 1997, 80:52-61.
34. Palaniyandi S.S., Sun L., Ferreira J.C., Mochly-Rosen D. Protein kinase C in heart failure: a therapeutic target?. Cardiovasc Res 2009, 82:229-239.
35. Konopatskaya O., Gilio K., Harper M.T., Zhao Y., Cosemans J.M., Karim Z.A., et al. PKCalpha regulates platelet granule secretion and thrombus formation in mice. J Clin Invest 2009, 119:399-407.
36. Wang G.S., Kuyumcu-Martinez M.N., Sarma S., Mathur N., Wehrens X.H., Cooper T.A. PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest 2009, 119:3797-3806.
37. The PKC-DRS Study Group Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol 2007, 125:318-324.
38. Jirousek M.R., Gillig J.R., Gonzalez C.M., Heath W.F., McDonald J.H., Neel D.A., et al. (S)-13-[(dimethylamino)methyl]-10, 11, 14, 15-tetrahydro-4, 9:16, 21-dimetheno-1H, 13H-dibenzo[e, k]pyrrolo[3, 4-h][1, 4, 13]oxadiazacyclohexadecene-1, 3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem 1996, 39:2664-2671.
39. Boyle A.J., Kelly D.J., Zhang Y., Cox A.J., Gow R.M., Way K., et al. Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction. J Mol Cell Cardiol 2005, 39:213-221.
40. Kong L., Andrassy M., Chang J.S., Huang C., Asai T., Szabolcs M.J., et al. PKCbeta modulates ischemia-reperfusion injury in the heart. Am J Physiol Heart Circ Physiol 2008, 294:H1862-H1870.
41. Connelly K.A., Kelly D.J., Zhang Y., Prior D.L., Advani A., Cox A.J., et al. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail 2009, 2:129-137.
42. Skvara H., Dawid M., Kleyn E., Wolff B., Meingassner J.G., Knight H., et al. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest 2008, 118:3151-3159.
43. Ramani G.V., Uber P.A., Mehra M.R. Chronic heart failure: contemporary diagnosis and management. Mayo Clin Proc 2010, 85:180-195.